UC Neuroscience Institute, Department of Neurology, Gardner Center for Parkinson's disease and Movement Disorders, University of Cincinnati, Cincinnati, Ohio 45267-0525, USA.
Mov Disord. 2011 Dec;26(14):2504-8. doi: 10.1002/mds.23893. Epub 2011 Sep 23.
Although movement impairment in Parkinson's disease includes slowness (bradykinesia), decreased amplitude (hypokinesia), and dysrhythmia, clinicians are instructed to rate them in a combined 0-4 severity scale using the Unified Parkinson's Disease Rating Scale motor subscale. The objective was to evaluate whether bradykinesia, hypokinesia, and dysrhythmia are associated with differential motor impairment and response to dopaminergic medications in patients with Parkinson's disease. Eighty five Parkinson's disease patients performed finger-tapping (item 23), hand-grasping (item 24), and pronation-supination (item 25) tasks OFF and ON medication while wearing motion sensors on the most affected hand. Speed, amplitude, and rhythm were rated using the Modified Bradykinesia Rating Scale. Quantitative variables representing speed (root mean square angular velocity), amplitude (excursion angle), and rhythm (coefficient of variation) were extracted from kinematic data. Fatigue was measured as decrements in speed and amplitude during the last 5 seconds compared with the first 5 seconds of movement. Amplitude impairments were worse and more prevalent than speed or rhythm impairments across all tasks (P < .001); however, in the ON state, speed scores improved exclusively by clinical (P < 10(-6) ) and predominantly by quantitative (P < .05) measures. Motor scores from OFF to ON improved in subjects who were strictly bradykinetic (P < .01) and both bradykinetic and hypokinetic (P < 10(-6) ), but not in those strictly hypokinetic. Fatigue in speed and amplitude was not improved by medication. Hypokinesia is more prevalent than bradykinesia, but dopaminergic medications predominantly improve the latter. Parkinson's disease patients may show different degrees of impairment in these movement components, which deserve separate measurement in research studies. © 2011 Movement Disorder Society.
虽然帕金森病的运动障碍包括运动缓慢(运动迟缓)、运动幅度减小(运动减少)和运动节律失调,但临床医生被指示使用统一帕金森病评定量表运动子量表将其在 0-4 严重程度量表中进行联合评分。目的是评估帕金森病患者的运动迟缓、运动减少和运动节律失调是否与运动障碍的不同程度和对多巴胺能药物的反应相关。85 例帕金森病患者在佩戴运动传感器的最受影响的手上进行手指敲击(项目 23)、手部抓握(项目 24)和旋前-旋后(项目 25)任务,OFF 药物和 ON 药物状态下。使用改良运动迟缓评定量表评定速度、幅度和节律。从运动学数据中提取速度(均方根角速度)、幅度(运动幅度角)和节律(变异系数)的定量变量。通过与运动前 5 秒相比,在运动后 5 秒期间速度和幅度的降低来衡量疲劳。在所有任务中,幅度障碍比速度或节律障碍更严重且更常见(P <.001);然而,在 ON 状态下,速度评分仅通过临床(P < 10(-6))和主要通过定量(P <.05)措施得到改善。OFF 到 ON 的运动评分在严格运动迟缓的患者中改善(P <.01)和严格运动迟缓及运动减少的患者中改善(P < 10(-6)),但在单纯运动减少的患者中没有改善。药物不能改善速度和幅度的疲劳。运动减少比运动迟缓更常见,但多巴胺能药物主要改善后者。帕金森病患者可能在这些运动成分中表现出不同程度的障碍,这些障碍在研究中值得单独测量。 © 2011 运动障碍协会。